Market
Standard of care for lung cancer by end of 2025?
2
Resolution / Starting Odds
RYBREVANT and LAZCLUZE • 25%
Tagrisso • 25%
Keytruda • 25%
Other • 25%
Healthcare guidelines and publications from major oncology associations
Story
Johnson & Johnson's RYBREVANT and LAZCLUZE Outperform Tagrisso, Promising Over One Year Survival Improvement Over Osimertinib
Jan 7, 2025, 01:11 PM
Johnson & Johnson announced that its lung cancer treatment, a combination of RYBREVANT® (amivantamab-vmjw) and LAZCLUZE™ (lazertinib), has shown a statistically significant and clinically meaningful improvement in overall survival compared to osimertinib. In a head-to-head study, this combination therapy outperformed AstraZeneca’s Tagrisso, which could potentially alter the standard of care for lung cancer, one of the most lethal tumor types. The company indicated that the median overall survival improvement is expected to exceed one year.
View original story
Similar markets
Other • 25%
Roche • 25%
AstraZeneca/Daiichi Sankyo • 25%
Pfizer • 25%
More than 80% • 25%
50% to 74% • 25%
Less than 50% • 25%
75% to 80% • 25%
Minimal adoption (<25% countries) • 25%
High adoption (75%+ countries) • 25%
Low adoption (25-49% countries) • 25%
Moderate adoption (50-74% countries) • 25%
Yes • 50%
No • 50%
No • 50%
Yes • 50%
Moderate coverage • 25%
No coverage • 25%
Limited coverage • 25%
Extensive coverage • 25%
No • 50%
Yes • 50%
Worse Outcomes • 25%
Significant Improvement • 25%
Moderate Improvement • 25%
No Change • 25%